| Trial ID: | L0437 |
| Source ID: | NCT00548912
|
| Associated Drug: |
Spironolactone
|
| Title: |
Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Failure, Chronic
|
| Interventions: |
DRUG: Spironolactone
|
| Outcome Measures: |
Primary: Left ventricular mass, 9 months |
|
| Sponsor/Collaborators: |
Sponsor: Dawnmarie DeFazio
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-10
|
| Completion Date: |
2008-10
|
| Results First Posted: |
|
| Last Update Posted: |
2021-12-09
|
| Locations: |
Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00548912
|
